PCRX:NAS (USA) Also trade in: Germany

Pacira BioSciences Inc

$ 35.9 -0.68 (-1.85%)
Volume: 407,684 Avg Vol (1m): 552,707
Market Cap $: 1.48 Bil Enterprise Value $: 1.39 Bil
P/E (TTM): 0.00 P/B: 4.58
Earnings Power Value 4.19
Net Current Asset Value 2.67
Tangible Book 6.3
Projected FCF 4.86
Median P/S Value 77.55
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

Current vs industry vs history
Cash-to-Debt 1.32
Equity-to-Asset 0.47
Debt-to-Equity 0.91
Debt-to-EBITDA 8.80
Interest Coverage 0.86
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.06
DISTRESS
GREY
SAFE
Beneish M-Score -2.74
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 8.83%
WACC 8.01%

Profitability & Growth : 6/10

Current vs industry vs history
Operating Margin % 5.18
Net Margin % -0.14
ROE % -0.16
ROA % -0.07
ROC (Joel Greenblatt) % 14.25
3-Year Total Revenue Growth Rate 10.60
3-Year Total EBITDA Growth Rate 16.90

» PCRX's 30-Y Financials

Financials (Next Earnings Date: 2019-05-03)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:PCRX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare TSX:APH BOM:524494 SZSE:002435 NAS:IPXL TSE:4547 NAS:RDUS NAS:ENDP SZSE:300485 SZSE:002550 ROCO:6446 SHSE:600557 TSE:4569 SHSE:600993 XBRU:FAGR XKRX:003520 BOM:533573 SZSE:300725 SZSE:300401 SHSE:600750 TSX:LEAF
Traded in other countries 82P.Germany
Address 5 Sylvan Way, Suite 300, Parsippany, NJ, USA, 07054
Pacira Pharmaceuticals is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and commercialization of pharmaceutical products, primarily for use in hospitals and ambulatory surgery centers. The company focuses its product candidates within the United States, and intends to out-license commercialization rights for other territories. Pacira aims to retain significant control over the development process and commercial execution for its product candidates.

Ratios

Current vs industry vs history
Forward PE Ratio 27.10
N/A
PB Ratio 4.58
PS Ratio 4.39
Price-to-Free-Cash-Flow 43.19
Price-to-Operating-Cash-Flow 30.29
EV-to-EBIT 69.76
EV-to-EBITDA 41.97
EV-to-Revenue 4.12
Current Ratio 7.88
Quick Ratio 7.08
Days Inventory 182.37
Days Sales Outstanding 41.12
Days Payable 60.39

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -3.50

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 5.7
Price-to-Projected-FCF 7.57
Price-to-Median-PS-Value 0.47
Earnings Yield (Joel Greenblatt) % 1.47

More Statistics

Revenue (TTM) (Mil) $ 337.28
EPS (TTM) $ -0.02
Beta 0.93
Volatility % 36.35
52-Week Range $ 30 - 55
Shares Outstanding (Mil) 41.22

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA N
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N